

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 10, 2016**

---

**Tandem Diabetes Care, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36189**  
(Commission  
File Number)

**20-4327508**  
(I.R.S. Employer  
Identification No.)

**11045 Roselle Street, San Diego, CA**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 366-6900**

**N/A**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Election of Director*

On March 10, 2016, Dr. Henry Anhalt, DO, FACOP, FACE, was elected to the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”). Dr. Anhalt will serve as a Class II director, with a term that expires at the annual meeting of stockholders of the Company to be held in 2018 or until his earlier resignation or removal. The Company’s Board of Directors (the “Board”) has affirmatively determined that Mr. Anhalt qualifies as an “independent director” under the NASDAQ Listing Rules.

Dr. Anhalt is 55 years old and is a pediatric endocrinologist. Since 2015, he has served as Chief Medical Officer of the T1D Exchange, a nonprofit organization fostering collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes. Prior to this appointment, Dr. Anhalt held numerous executive positions in the medical device and biopharmaceutical industries. From November 2012 until March 2015 he served in various roles with Sanofi North America, where he was most recently Senior Medical Director in Medical Diabetes. Prior to that, he was the Chief Medical Officer and Medical Director of the Artificial Pancreas program at Animas, Inc., a Johnson and Johnson Company. Dr. Anhalt also had a long academic career, including leading the pediatric endocrinology fellowship training program at the State University of New York in Brooklyn. He received his B.A. from Yeshiva University, a D.O. from the New York College of Osteopathic Medicine and completed his pediatric endocrinology fellowship at the Lucille Salter Packard Children’s Hospital at Stanford University.

*No Arrangements or Understandings*

There is no arrangement or understanding pursuant to which Mr. Anhalt was elected to the Board.

*No Related Party Transactions*

Except as described or referenced herein, Mr. Anhalt has not entered into any transactions (i) with the Company, (ii) with any of the Company’s directors, nominees for election as a director, or executive officers, (iii) with any security holder who is known to the Company to own of record or beneficially more than five percent (5.0%) of any class of the Company’s voting securities, or (iv) with any member of the immediate family of any of the foregoing persons, in amounts greater than \$120,000, nor are any such transactions contemplated.

*Compensatory Arrangements*

Dr. Anhalt will be eligible to participate in the director compensation plans and arrangements available to the Company’s other independent directors. Accordingly, upon his appointment, Mr. Anhalt was granted an option to purchase 25,000 shares of the Company’s common stock under the Company’s 2013 Stock Incentive Plan with an exercise price equal to the closing price of the common stock on the grant date. The option will vest in equal monthly installments over a period of 36 months following the grant date, subject to Mr. Anhalt’s continued service with the Company.

*Issuance of Press Release*

On March 14, 2016, the Company issued a press release announcing Mr. Anhalt’s election to the Board. The full text of the press release is attached hereto as Exhibit 99.1 and is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Number    Description**

99.1        Press release of Tandem Diabetes Care, Inc. dated March 14, 2016.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

Date: March 14, 2016

/s/ David B. Berger

David B. Berger

Executive Vice President, General Counsel and Secretary

---

## INDEX TO EXHIBITS

<b><u>Number</u></b>	<b><u>Description</u></b>
----------------------	---------------------------

99.1	Press release of Tandem Diabetes Care, Inc. dated March 14, 2016.
------	---

**Media Contact:**

Steve Sabicer  
714-907-6264  
[ssabicer@thesabicergroup.com](mailto:ssabicer@thesabicergroup.com)

**Investor Contact:**

Susan Morrison  
858-366-6900 x7005  
[smorrison@tandemdiabetes.com](mailto:smorrison@tandemdiabetes.com)

**FOR IMMEDIATE RELEASE****Tandem Diabetes Care Announces Appointment of Dr. Henry Anhalt as Board Member**

**San Diego, March 14, 2016** – Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today announced the appointment of Henry Anhalt, DO, FACOP, FACE as an independent member of its board of directors. Dr. Anhalt is a practicing pediatric endocrinologist and chief medical officer of T1D Exchange, a nonprofit organization fostering collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes.

“Henry is a renowned, patient-centric physician whose passion for helping people with diabetes aligns with our Company’s mission, and we welcome him to our Board,” said Kim Blickenstaff, president and CEO, Tandem Diabetes Care. “His breadth of clinical and industry experience in diabetes care, and his deep understanding of automated insulin delivery, brings tremendous value to our Company as we advance our product development efforts and grow our business.”

Prior to his current appointment at T1D Exchange, Dr. Anhalt held numerous executive positions in the medical device and biopharmaceutical industries. He was Senior Medical Director in Medical Diabetes at Sanofi North America and was responsible for developing and executing the North American Medical affairs strategy for Toujeo, a long-acting basal insulin. Prior to that he was the Chief Medical Officer and Medical Director of the Artificial Pancreas program at Animas, Inc. a Johnson and Johnson Company.

---

Dr. Anhalt has had a long academic career during which he led the pediatric endocrinology fellowship training program at the State University of New York in Brooklyn. He has published more than 30 peer-reviewed papers, four textbook chapters, and dozens of clinical abstracts. Dr. Anhalt has held senior leadership positions in many professional organizations and currently serves as chair of the Hormone Health Network of the Endocrine Society. He received his B.A. from Yeshiva University, a D.O. from the New York College of Osteopathic Medicine and completed his pediatric endocrinology fellowship at the Lucille Salter Packard Children's Hospital at Stanford University.

**About Tandem Diabetes Care, Inc.**

Tandem Diabetes Care, Inc. ([www.tandemdiabetes.com](http://www.tandemdiabetes.com)) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim, #tslimG4, #tflex, #tconnect, and \$TNDM.

Follow Tandem Diabetes Care on Facebook at [www.facebook.com/TandemDiabetes](http://www.facebook.com/TandemDiabetes).

Follow Tandem Diabetes Care on LinkedIn at <https://www.linkedin.com/company/TandemDiabetes>.

t:slim, t:flex and Tandem Diabetes Care are registered trademarks, and t:slim G4 is a trademark of Tandem Diabetes Care, Inc.

###